1Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60: 277-300.
2Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, et al. (2007) Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle 6: 2010-2018.
3Cohen A, Shmoish M, Levi L, Cheruti U, Levavi-Sivan B, et al. (2008) Alterations in micro-ribonucleic acid expression profiles reveal a novel pathway for estrogen regulation. Endocrinology 149: 1687-96.
4Johnston SJ, Cheung KL (2010) Fulvestrant - a novel endocrine therapy for breast cancer. Curr Med Chem 17: 902-914.
5Saxena R, Dwivedi A (2010) ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Med Res Rev 32:166-215.
6Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, et al. (1991) Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83: 1299-1306.
7Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, et al. (2003) Update on estrogen signaling. FEBS Lett 546, 17-24.
8Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
9Kaklamani VG, Gradishar WJ (2005) Adjuvant therapy of breast cancer. Cancer Invest 23: 548-560.
10Nahta R, Esteva FJ (2003) HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 9: 5078-5084.
11Hudis CA (2007) Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 357: 39-51.
12Carthew RW, Sontheimer EJ (2009) Origins and Mechanisms of miRNAs and siRNAs. Cell 136: 642-655.
13Lee HY, Zhou K, Smith AM, Noland CL, Doudna JA (2013) Differential roles of human Dicer-binding proteins TRBP and PACT in small RNA processing. Nucleic Acids Res 41: 6568-6576.
14Perron MP, Provost P (2008) Protein interactions and complexes in human microRNA biogenesis and function. Front Biosci 13: 2537-47.
15Redfern AD, Colley SM, Beveridge DJ, Ikeda N, Epis MR, et al. (2013) RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators. Proc Natl Acad Sci U S A 110: 6536-6541.
16Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101: 2999-3004.
17Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398.
18Hu Z, Fan C, Oh DS, Marron JS, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.
19Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93: 5925-5930.
20Weigel NL, Zhang Y (1998) Ligand-independent activation of steroid hormone receptors. J Mol Med 76: 469-479.
21Webb P, Lopez GN, Uht RM, Kushner PJ (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9: 443-456.
22Cunha GR, Cooke PS, Kurita T (2004) Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 67: 417-434.
23Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-12.
24Xu J, Li Q (2003) Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17: 1681-1692.
25Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, et al. (2004) High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6: 263-274.
26Järvinen TA, Pelto-Huikko M, Holli K, Isola J (2000) Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156: 29-35.
27Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, et al. (2005) Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12: 903-916.
28Leung YK, Mak P, Hassan S, Ho SM (2006) Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A 103: 13162-13167.
29Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, et al. (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201: 213-220.
30Lin CY, Ström A, Li Kong S, Kietz S, Thomsen JS, et al. (2007) Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res 9: R25.
31Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, et al. (2013) Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet 9: e1003311.
32Zhao G, Guo J, Li D, Jia C, Yin W, et al. (2013) MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line. DNA Cell Biol 32: 699-707.
33Sachdeva M, Wu H, Ru P, Hwang L, Trieu V, et al. (2011) MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene 30: 822-831.
34Jordan VC, O'Malley BW (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25: 5815-5824.
35Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, et al. (2009) The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A 106: 15732-15737.
36de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, et al. (2010) Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 70: 9175-9184.
37Adams BD, Furneaux H, White BA (2007) The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 21: 1132-1147.
38Li X, Mertens-Talcott SU, Zhang S, Kim K, Ball J, et al. (2010) MicroRNA-27a Indirectly Regulates Estrogen Receptor {alpha} Expression and Hormone Responsiveness in MCF-7 Breast Cancer Cells. Endocrinology 151: 2462-2473.
39Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, et al. (2010) Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31: 2049-2057.
40He YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, et al. (2013) miR-342 is associated with estrogen receptor-alpha expression and response to tamoxifen in breast cancer. Exp Ther Med 5: 813-818.
41Hossain A, Kuo MT, Saunders GF (2006) Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 26: 8191-8201.
42Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, et al. (2010) miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 17: 246-254.
43Xiong J, Yu D, Wei N, Fu H, Cai T , et al. (2010) An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 277: 1684-1694.
44Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S (2009) Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 28: 3926-3936.
45Leivonen SK, Rokka A, Ostling P, Kohonen P, Corthals GL, et al. (2011) Identification of miR-193b targets in breast cancer cells and systems biological analysis of their functional impact. Mol Cell Proteomics 10: M110.005322.
46Wang M, Yu B, Westerlind K, Strange R, Khan G, et al. (2009) Prepubertal physical activity up-regulates estrogen receptor beta, BRCA1 and p53 mRNA expression in the rat mammary gland. Breast Cancer Res Treat 115: 213-220.
47Paris O, Ferraro L, Grober OM, Ravo M, De Filippo MR, et al. (2012) Direct regulation of microRNA biogenesis and expression by estrogen receptor beta in hormone-responsive breast cancer. Oncogene 31: 4196-4206.
48Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, et al. (2010) Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res 70: 4778-4784.
49Nam S, Long X, Kwon C, Kim S, Nephew KP (2012) An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells. BMC Genomics 13: 732.
50Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, et al. (2010) MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 102: 706-721.
51Zhao JJ, Lin J, Yang H, Kong W, He L, et al. (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283: 31079-31086.
52Rao X, Di Leva G, Li M, Fang F, Devlin C, et al. (2011) MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30: 1082-1097.
53Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, et al. (2007) Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 619: 30-37.
54Masri S, Liu Z, Phung S, Wang E, Yuan YC, et al. (2010) The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat 124: 89-99.
55Alters SE, McLaughlin B, Spink B, Lachinyan T, Wang CW, et al. (2013) GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's. PLoS One 7:e50630.
56Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, et al. (2011) miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41: 210-220.
57Walter BA, Gómez-Macias G, Valera VA, Sobel M, Merino MJ (2011) miR-21 Expression in Pregnancy-Associated Breast Cancer: A Possible Marker of Poor Prognosis. J Cancer 2: 67-75.
58Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, et al. (2011) Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat 127: 69-80.
59Lehmann TP1, Korski K, Ibbs M, Zawierucha P, Grodecka-Gazdecka S, et al. (2013) rs12976445 variant in the pri-miR-125a correlates with a lower level of hsa-miR-125a and ERBB2 overexpression in breast cancer patients. Oncol Lett 5: 569-573.